Title
Category
Credits
Event date
Cost
CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities. Although these toxicities are generally reversible, early recognition and implementation of an appropriate management strategy are essential.
Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies
  • Acute Lymphoblastic Leukemia
  • Hematologic Malignancies
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies. Bispecific antibodies represent a novel immunotherapy approach with remarkable efficacy for the treatment of relapsed/refractory hematologic malignancies. However, they also have a distinct toxicity profile associated with T-cell activation.